<DOC>
	<DOCNO>NCT03010332</DOCNO>
	<brief_summary>This expand access protocol design provide access ATA230 subject cytomegalovirus ( CMV ) viremia disease , intolerant , fail , standard antiviral therapy comparable treatment option .</brief_summary>
	<brief_title>Expanded Access Protocol ATA230 ( Third-Party Donor-Derived CMV-CTLs ) Treatment CMV Viremia Disease</brief_title>
	<detailed_description>ATA230 ( third-party donor-derived CMV-CTLs ) cytotoxic T lymphocytes specifically kill cell present CMV protein antigens . This expand access protocol design provide access ATA230 subject CMV viremia disease , intolerant , fail , standard antiviral therapy comparable treatment option . This study enroll subject regardless underlie susceptibility CMV , include allogeneic hematopoietic cell transplant ( alloHCT ) , solid organ transplant ( SOT ) , human immunodeficiency virus ( HIV ) , immunocompromised state , immune competent subject require therapy . Subjects must active CMV viremia disease ≥ 2 week despite treatment antiviral therapy must intolerant antiviral therapy due treatment-related toxicity comorbidities renal insufficiency myelosuppression . ATA230 administer cycle last 5 week ( 35 day ) . During cycle , subject receive intravenous ( IV ) ATA230 dose 1×10^6 cells/kg ( acceptable range 0.8-1.0×10^6 cells/kg ) Days 1 , 8 , 15 , follow observation Day 35 .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<criteria>A subject consider eligible participate study follow inclusion criterion satisfy : 1 . Has clinically document condition associate CMV disease ( eg , interstitial pneumonia , hepatitis , encephalitis , retinitis , colitis ) microbiological evidence CMV viremia tissue invasion CMV infection ( determined viral culture level CMV DNA blood body fluid ) 2 . The CMV disease CMV viremia characterize least one following : 1 . CMV disease persistent clinically progress despite ≥ 2 week antiviral therapy 2 . CMV viremia/disease persistent increase ( determine quantitation blood CMV DNA ) despite ≥ 2 week antiviral therapy 3 . A genetic mutation associate antiviral drug resistance present 4 . Unable continue antiviral drug due drugassociated toxicity . 3 . No comparable satisfactory therapy available treatment CMV 4 . Not eligible trial support development ATA230 5 . For subject receive alloHCT , underlie disease alloHCT perform morphologic remission 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3× upper limit normal ( ULN ) total bilirubin &lt; 2.5×ULN unless cause CMV 7 . Availability appropriate ATA230 cell lot ( ie , HLA partiallymatched restrict CMVCTLs ) 8 . Subject subject 's representative willing able provide write informed consent A subject eligible participate study follow criterion meet : 1 . Receiving concomitant investigational therapy ( coenrollment noninterventional study study followup sample collection permit ) 2 . Need antimetabolite agent ( eg , methotrexate ) , extracorporeal photopheresis 3 . Antithymocyte globulin similar antiT cell antibody therapy ≤ 4 week prior first dose ATA230 ( Day 1 Cycle 1 ) 4 . Need vasopressor ventilator support 5 . Pregnancy , except ATA230 clearly need 6 . Female childbearing potential male female partner childbearing potential unwilling use highly effective method contraception 7 . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Cytomegalovirus Viremia</keyword>
	<keyword>Cytomegalovirus Infection</keyword>
	<keyword>CMV Infection</keyword>
	<keyword>Hematopoietic Cell Transplant</keyword>
	<keyword>Solid Organ Transplant</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Cytomegalovirus Disease</keyword>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>CMV</keyword>
	<keyword>CMV syndrome</keyword>
	<keyword>Cytomegalovirus syndrome</keyword>
	<keyword>CMV disease</keyword>
	<keyword>CMV viremia</keyword>
	<keyword>allogeneic</keyword>
	<keyword>third-party</keyword>
</DOC>